Kirchgraber Paul R 4
4 · LABORATORY CORP OF AMERICA HOLDINGS · Filed Nov 3, 2022
Insider Transaction Report
Form 4
Kirchgraber Paul R
CEO, Covance Drug Development
Transactions
- Tax Payment
Common Stock
2022-11-01$222.56/sh−892$198,524→ 13,030 total - Exercise/Conversion
Restricted Stock Unit
2022-11-01−2,007→ 2,897 total→ Common Stock (2,007 underlying) - Exercise/Conversion
Common Stock
2022-11-01+2,007→ 13,922 total
Footnotes (4)
- [F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- [F2]Stock withholding to satisfy tax withholding obligations.
- [F3]The Restricted Stock Units vested in three equal annual installments beginning on November 1, 2020 and are now fully vested.
- [F4]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.